np1: A computer program for dose escalation strategies in phase I clinical trials

Computer Methods and Programs in Biomedicine

Volumn 88, Issue 1, 2007, Pages 8-17

  Kramar, Andrew ^a   Houédé, Nadine ^b   Paoletti, Xavier ^c  

^a CENTRE VAL D AURELLE   (France)

^b INSTITUT BERGONIÉ   (France)

^c INSTITUT NATIONAL DU CANCER   (France)

Author keywords

Computer program; Dose escalation; np1; Phase I trial

Indexed keywords

COMPUTER PROGRAMMING; DRUG DOSAGE; PATIENT TREATMENT;

CONTINUAL REASSESSMENT METHODS; DOSE ESCALATION;

COMPUTER SOFTWARE;

ARTICLE; BAYES THEOREM; CLINICAL RESEARCH; COMPUTER PROGRAM; COMPUTER SIMULATION; HUMAN; HUMAN COMPUTER INTERACTION; INTERMETHOD COMPARISON; MAXIMUM TOLERATED DOSE; MEDICAL PRACTICE; PARAMETER; STATISTICAL ANALYSIS;

BAYES THEOREM; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; SOFTWARE;

EID: 34548264291     PISSN: 01692607     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmpb.2007.06.006     Document Type: Article

References (18)

1. Roberts Jr. T.G., Goulart B.H., Squitieri L., Stallings S.C., Halpern E.F., Chabner B.A., Gazelle G.S., Finkelstein S.N., and Clark J.W. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292 (2004) 2130-2140
2. Collins J.M. Innovations in phase 1 trial design: where do we go next?. Clin. Cancer Res. 6 (2000) 3801-3802
3. Eisenhauer E.A., O'Dwyer P.J., Christian M., and Humphrey J.S. Phase I clinical trial design in cancer drug development. J. Clin. Oncol. 18 (2000) 684-692
4. O'Quigley J., Pepe M., and Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46 (1990) 33-48
5. O'Quigley J., and Shen L.Z. Continual reassessment method: a likelihood approach. Biometrics 52 (1996) 673-684
6. Lin Y., and Shih W.J. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2 (2001) 203-215
7. Reiner E., Paoletti X., and O'Quigley J. Operating characteristics of the standard phase I clinical trial design. Comput. Stat. Data Anal. 30 (1999) 303-315
8. Gooley T.A., Martin P.J., Fisher L.D., and Pettinger M. Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. Control Clin. Trials 15 (1994) 450-462
9. Storer B.E. Design and analysis of phase I clinical trials. Biometrics 45 (1989) 925-937
10. Kramar A., Lebecq A., and Candalh E. Continual reassessment methods in phase I trials of the combination of two drugs in oncology. Stat. Med. 18 (1999) 1849-1864
11. Moller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat. Med. 14 (1995) 911-922 discussion 923
12. Faries D. Practical modifications of the continual reassessment method for phase I cancer clinical trials. J. Biopharm. Stat. 4 (1994) 147-164
13. Goodman S.N., Zahurak M.L., and Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat. Med. 14 (1995) 1149-1161
14. Thall P.F., Lee J.J., Tseng C.H., and Estey E.H. Accrual strategies for phase I trials with delayed patient outcome. Stat. Med. 18 (1999) 1155-1169
15. Abbruzzese J.L., Grunewald R., Weeks E.A., Gravel D., Adams T., Nowak B., Mineishi S., Tarassoff P., Satterlee W., Raber M.N., et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol. 9 (1991) 491-498
16. O'Quigley J., and Reiner E. A stopping rule for the continual reassessment method. Biometrika 85 (1998) 741-748
17. Paoletti X., O'Quigley J., and Maccario J. Design efficiency in dose finding studies. Comput. Stat. Data Anal. 45 (2004) 197-214
18. O'Quigley J., Paoletti X., and Maccario J. Non-parametric optimal design in dose finding studies. Biostatistics 3 (2002) 51-56